Developer docs
API playgroundTry for free, no card

Search company profiles

ProtaGene

Full company profile

uuid00083rb

Namestring
ProtaGene
Legal namestring
ProtaGene Group
Websiteurl
protagene.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

ProtaGene is a privately held contract research organization (CRO) headquartered in Heilbronn, Germany, with additional operations in Dortmund and Heidelberg (Germany) and Burlington, Massachusetts. The company delivers advanced analytical services to biopharmaceutical developers and cell and gene therapy (CGT) innovators, spanning protein biotherapeutic characterization, biosimilar comparability studies, gene therapy vector analytics, integration site analysis (ISA), molecular bioanalysis, gene expression quantitation, and commercial patient testing for approved advanced therapy medicinal products (ATMPs). Its two interconnected service lines — Biologic Drug Analytics and Cell & Gene Therapeutic Analytics — are supported by an Analytical Systems platform built on Thermo Q Exactive and Orbitrap mass spectrometers, Bruker QTOF instruments, HPLC and SPR systems, and Illumina MiSeq and Oxford Nanopore sequencing platforms.

ProtaGene operates a project-based, quote-driven professional services model, including a multi-year Customized-Candidate Analytical Development (C-CAD) strategic partnering program that assigns a dedicated CMC Molecule Manager to coordinate end-to-end analytical responsibility from candidate selection through commercialization. The company maintains GMP certification (since 2006 at its German sites, with US expansion forthcoming), GLP accreditation at Heidelberg (2024), GCLP and GCP compliance, CLIA registration in Massachusetts, and IVDR Article 5(5) conformity for two ISA components (May 2025). Its proprietary methods — notably LAM-PCR for vector integration site analysis, originated by GeneWerk co-founders Dr. Manfred Schmidt and Prof. Dr. Christof von Kalle, and S-EPTS/LM-PCR for gene editing safety assessment — are deeply embedded in regulatory submissions for approved gene therapies, including historical work on Glybera, the first approved gene therapy in a Western country.

ProtaGene traces its lineage to Protagen GbR (1997 spin-out from Ruhr-University Bochum), BioAnalytix (2012, Barnett Institute), and GeneWerk (founded 2014 by Schmidt, von Kalle, and Annette Deichmann). The current entity was formed by the 2016 merger of Protagen Protein Services with BioAnalytix, the July 2021 merger with GeneWerk, and the January 2022 rebranding to ProtaGene. Ampersand Capital Partners, which first backed GeneWerk in 2019, made an additional investment in November 2023 to support further expansion. The company sells through enterprise field sales and strategic partnerships, most recently signing a strategic partnership with Merck Life Science announced for May 2026 to broaden biologics testing solutions.

Short descriptiontext

ProtaGene is a privately held CRO providing advanced analytical services — including protein characterization, biosimilar comparability, gene therapy vector analytics, and integration site analysis — to biopharmaceutical developers and cell and gene therapy innovators across Europe and North America.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersHeilbronn, Germany
HQ citystring
Heilbronn
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharmaceutical analytical services, biologics characterization services, cell therapy analytics, gene therapy safety testing, integration site analysis
Industry3 codes
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)
SECONDARYHLAGAFAC
DMPK / ADME & Bioanalysis
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Biopharmaceutical Analytical CRO Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Research Services
TypeProfessional Services
Description

Project-based analytical testing and characterization services for biopharmaceutical and cell/gene therapy developers. Services span from research through commercial product release, including GMP lot release testing, stability testing, and regulatory submission support.

protagene.com
2Strategic Program Partnering (C-CAD)
TypeProfessional Services
Description

Customized-Candidate Analytical Development partnerships providing end-to-end analytical development responsibility from candidate to market, with dedicated CMC Molecule Manager coordination.

protagene.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

ProtaGene is a contract research organization providing advanced analytical laboratory services for biopharmaceutical and cell/gene therapy developers. The company offers two integrated service lines — Biologic Drug Analytics (biotherapeutic characterization, product and process development, manufacturing and QC, biosimilar program support, clinical sample in vivo CQA mapping, and cell-based assays) and Cell & Gene Therapeutic Analytics (molecular bioanalysis, integration site analysis, vector analytics, long-read sequencing, bioinformatics, genome and gene editing analysis, gene expression analysis, and commercial patient testing) — delivered through GMP-, GLP-, GCP-, GCLP-, and CLIA-certified facilities across Germany and the United States.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Over 25 biosimilar molecules successfully supported for clients
+1 more record
Product overview1 text field

ProtaGene is a world-leading CRO providing advanced, integrated, and complete analytical solutions for the biopharmaceutical and cell & gene therapy industries. The company operates two interconnected service lines: Biologic Drug Analytics (encompassing Biotherapeutic Characterization Services, Product and Process Development, Manufacturing and QC, Biosimilar Program Support, Clinical Sample In Vivo CQA Mapping, and Cell-based Assays) and Cell & Gene Therapeutic Analytics (encompassing Molecular Bioanalysis, Integration Site Analysis, Vector Analytics, Long-Read Sequencing Services, Bioinformatics, Genome and Gene Editing Analysis, Gene Expression Analysis, and Commercial Patient Testing). Supporting these service lines are Analytical Systems and the C-CAD strategic partnership program. The organization was established in 2021 through the merger of Protagen Protein Services, BioAnalytix, and GeneWerk, operating four sites in Germany (Heilbronn, Dortmund, Heidelberg) and the USA (Burlington, MA).

Product and service4 records
1Biologic Drug Analytics
CategoryBiologics analytical services
Description

Integrated analytical service line providing advanced analytics and complete data packages for all stages of biotherapeutic development (including biotherapeutic characterization, product and process development, manufacturing and QC, biosimilar program support, clinical sample in vivo CQA mapping, and cell-based assays) for biopharmaceutical developers from early discovery through commercial product release.

2Cell & Gene Therapeutic Analytics
CategoryCell and gene therapy analytical services
Description

Integrated analytical development service line for gene therapy and cell therapy programs, combining molecular bioanalysis, viral vector characterization, integration site analysis, long-read sequencing, bioinformatics, genome and gene editing analysis, gene expression analysis, and commercial patient testing from discovery through clinical trials and post-marketing safety monitoring.

3Commercial Patient Testing
CategoryClinical patient testing services
Description

Patient sample testing in support of safety monitoring protocols for approved gene therapy products, including Integration Site Analysis (ISA) and Vector Copy Number (VCN) testing performed at CLIA-certified sites for sponsors of approved ATMPs.

4Customized-Candidate Analytical Development (C-CAD)
CategoryStrategic program partnering
Description

Strategic partnership program providing full responsibility and coordination for analytical programs across all stages of molecule development from clone to clinic to market, with a dedicated CMC Molecule Manager coordinating end-to-end analytical development for clients seeking comprehensive program partnering.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-05-15
Description

Strategic partnership announced to expand comprehensive biologics testing solutions. The partnership combines ProtaGene's analytical expertise with Merck's life science business capabilities to provide enhanced service offerings for biologics developers.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

ABL Bio is a specialized gene therapy CDMO/CRO offering viral vector manufacturing, biosafety testing, and integration site analysis services. Comparable to ProtaGene on cell/gene therapy analytics, with deeper manufacturing integration but narrower biotherapeutic protein characterization offerings.

TypeEmerging player
Description

GenScript ProBio provides CDMO and analytical services for biologics and cell/gene therapy developers, including vector characterization and biosafety testing. Comparable to ProtaGene on gene therapy and biologics analytics with growing specialty depth, particularly in viral vector and plasmid analytics.

TypeBroad incumbent
Description

Labcorp Drug Development offers central lab, bioanalytical, and biologics characterization services with global lab infrastructure. Competes with ProtaGene on protein characterization and biosimilar comparability work, but with substantially broader clinical and central lab services and less ISA specialization.

TypeEmerging player
Description

WuXi AppTec's Advanced Therapies unit provides analytical testing and CMC services for cell and gene therapy developers, including viral vector characterization and biosafety testing. Comparable to ProtaGene on gene therapy analytics, with broader CDMO scale but less specialization in ISA and biosimilar comparability.

TypeBroad incumbent
Description

Thermo Fisher Scientific acquired PPD and operates bioanalytical and biologics characterization labs that overlap with ProtaGene's mass spectrometry, GMP testing, and biosimilar characterization services. Has broader life sciences scale and instrument manufacturer position, but less focus on gene therapy ISA.

TypeDirect peer
Description

BioReliance, the biopharma biosafety testing arm of MilliporeSigma (Merck KGaA), offers biosafety, viral clearance, and biologics characterization services including integration site analysis. Direct competitor to ProtaGene's Cell & Gene Therapy Analytics line, particularly on ISA, viral vector testing, and GMP lot release services for biologics developers.

TypeBroad incumbent
Description

Intertek Pharmaceutical Services provides analytical development, GMP testing, and biologics characterization across global labs. Comparable to ProtaGene on biologics and biosimilar testing services, though with less specialization in cell/gene therapy integration site analysis.

TypeBroad incumbent
Description

Eurofins BioPharma Product Testing is the largest global contract testing network for biopharmaceuticals, offering biologics characterization, biosimilar comparability, viral clearance, and cell/gene therapy analytics. Overlaps with ProtaGene across nearly all service lines at greater scale and broader geographic reach, though it is a portfolio rather than specialty provider.

TypeBroad incumbent
Description

Charles River's Biologics and Cell & Gene Therapy CDMO/CRO services include analytical method development, biosafety testing, viral clearance, and cell therapy characterization. Competes with ProtaGene on biologics characterization and cell/gene therapy analytics, with deeper CDMO integration but less specialization in ISA and biosimilar comparability.

TypeBroad incumbent
Description

SGS Health Sciences provides bioanalytical, biosafety, and biopharmaceutical characterization services from a global laboratory network. Overlaps with ProtaGene on biologics testing, GMP release, and biosafety testing, though at broader scale with less focus on gene therapy ISA.

Market position
Strengths2 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance8 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ProtaGene

Biopharmaceutical Analytical CRO Servicesprotagene.com

ProtaGene is a privately held CRO providing advanced analytical services — including protein characterization, biosimilar comparability, gene therapy vector analytics, and integration site analysis — to biopharmaceutical developers and cell and gene therapy innovators across Europe and North America.

What ProtaGene does

ProtaGene is a privately held contract research organization (CRO) headquartered in Heilbronn, Germany, with additional operations in Dortmund and Heidelberg (Germany) and Burlington, Massachusetts. The company delivers advanced analytical services to biopharmaceutical developers and cell and gene therapy (CGT) innovators, spanning protein biotherapeutic characterization, biosimilar comparability studies, gene therapy vector analytics, integration site analysis (ISA), molecular bioanalysis, gene expression quantitation, and commercial patient testing for approved advanced therapy medicinal products (ATMPs). Its two interconnected service lines — Biologic Drug Analytics and Cell & Gene Therapeutic Analytics — are supported by an Analytical Systems platform built on Thermo Q Exactive and Orbitrap mass spectrometers, Bruker QTOF instruments, HPLC and SPR systems, and Illumina MiSeq and Oxford Nanopore sequencing platforms.

ProtaGene operates a project-based, quote-driven professional services model, including a multi-year Customized-Candidate Analytical Development (C-CAD) strategic partnering program that assigns a dedicated CMC Molecule Manager to coordinate end-to-end analytical responsibility from candidate selection through commercialization. The company maintains GMP certification (since 2006 at its German sites, with US expansion forthcoming), GLP accreditation at Heidelberg (2024), GCLP and GCP compliance, CLIA registration in Massachusetts, and IVDR Article 5(5) conformity for two ISA components (May 2025). Its proprietary methods — notably LAM-PCR for vector integration site analysis, originated by GeneWerk co-founders Dr. Manfred Schmidt and Prof. Dr. Christof von Kalle, and S-EPTS/LM-PCR for gene editing safety assessment — are deeply embedded in regulatory submissions for approved gene therapies, including historical work on Glybera, the first approved gene therapy in a Western country.

ProtaGene traces its lineage to Protagen GbR (1997 spin-out from Ruhr-University Bochum), BioAnalytix (2012, Barnett Institute), and GeneWerk (founded 2014 by Schmidt, von Kalle, and Annette Deichmann). The current entity was formed by the 2016 merger of Protagen Protein Services with BioAnalytix, the July 2021 merger with GeneWerk, and the January 2022 rebranding to ProtaGene. Ampersand Capital Partners, which first backed GeneWerk in 2019, made an additional investment in November 2023 to support further expansion. The company sells through enterprise field sales and strategic partnerships, most recently signing a strategic partnership with Merck Life Science announced for May 2026 to broaden biologics testing solutions.

ProtaGene firmographics

Firmographics
Name
ProtaGene
Legal name
ProtaGene Group
Website
https://protagene.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
101–250 employees
Short description
ProtaGene is a privately held CRO providing advanced analytical services — including protein characterization, biosimilar comparability, gene therapy vector analytics, and integration site analysis — to biopharmaceutical developers and cell and gene therapy innovators across Europe and North America.
Ownership category
akta.pro rank

Where ProtaGene is headquartered

Location

Headquarters

HQ city
Heilbronn
HQ country
Germany
HQ region
Europe

Offices4 records

Markets served

ProtaGene business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Contract Research Services: Project-based analytical testing and characterization services for biopharmaceutical and cell/gene therapy developers. Services span from research through commercial product release, including GMP lot release testing, stability testing, and regulatory submission support.
  2. Strategic Program Partnering (C-CAD): Customized-Candidate Analytical Development partnerships providing end-to-end analytical development responsibility from candidate to market, with dedicated CMC Molecule Manager coordination.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

ProtaGene product offering

Product offering

Core offering

ProtaGene is a contract research organization providing advanced analytical laboratory services for biopharmaceutical and cell/gene therapy developers. The company offers two integrated service lines — Biologic Drug Analytics (biotherapeutic characterization, product and process development, manufacturing and QC, biosimilar program support, clinical sample in vivo CQA mapping, and cell-based assays) and Cell & Gene Therapeutic Analytics (molecular bioanalysis, integration site analysis, vector analytics, long-read sequencing, bioinformatics, genome and gene editing analysis, gene expression analysis, and commercial patient testing) — delivered through GMP-, GLP-, GCP-, GCLP-, and CLIA-certified facilities across Germany and the United States.

Product overview

ProtaGene is a world-leading CRO providing advanced, integrated, and complete analytical solutions for the biopharmaceutical and cell & gene therapy industries. The company operates two interconnected service lines: Biologic Drug Analytics (encompassing Biotherapeutic Characterization Services, Product and Process Development, Manufacturing and QC, Biosimilar Program Support, Clinical Sample In Vivo CQA Mapping, and Cell-based Assays) and Cell & Gene Therapeutic Analytics (encompassing Molecular Bioanalysis, Integration Site Analysis, Vector Analytics, Long-Read Sequencing Services, Bioinformatics, Genome and Gene Editing Analysis, Gene Expression Analysis, and Commercial Patient Testing). Supporting these service lines are Analytical Systems and the C-CAD strategic partnership program. The organization was established in 2021 through the merger of Protagen Protein Services, BioAnalytix, and GeneWerk, operating four sites in Germany (Heilbronn, Dortmund, Heidelberg) and the USA (Burlington, MA).

Differentiator

Problem solved

Functional benefit

Products and services

  • Biologic Drug Analytics Integrated analytical service line providing advanced analytics and complete data packages for all stages of biotherapeutic development (including biotherapeutic characterization, product and process development, manufacturing and QC, biosimilar program support, clinical sample in vivo CQA mapping, and cell-based assays) for biopharmaceutical developers from early discovery through commercial product release.
  • Cell & Gene Therapeutic Analytics Integrated analytical development service line for gene therapy and cell therapy programs, combining molecular bioanalysis, viral vector characterization, integration site analysis, long-read sequencing, bioinformatics, genome and gene editing analysis, gene expression analysis, and commercial patient testing from discovery through clinical trials and post-marketing safety monitoring.
  • Commercial Patient Testing Patient sample testing in support of safety monitoring protocols for approved gene therapy products, including Integration Site Analysis (ISA) and Vector Copy Number (VCN) testing performed at CLIA-certified sites for sponsors of approved ATMPs.
  • Customized-Candidate Analytical Development (C-CAD) Strategic partnership program providing full responsibility and coordination for analytical programs across all stages of molecule development from clone to clinic to market, with a dedicated CMC Molecule Manager coordinating end-to-end analytical development for clients seeking comprehensive program partnering.

Quantifiable outcome

  • Over 25 biosimilar molecules successfully supported for clients
  • +1 more outcomes

Companies that use ProtaGene

Customer profile

Segments3 records

Ideal customer profiles3 records

ProtaGene technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

ProtaGene partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Merck Life SciencestrategicStrategic or Co-development Partner · 15 May 2026Strategic partnership announced to expand comprehensive biologics testing solutions. The partnership combines ProtaGene's analytical expertise with Merck's life science business capabilities to provide enhanced service offerings for biologics developers.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

ProtaGene competitors and assessment

Company assessment

Emerging players

  • ABL Bio: ABL Bio is a specialized gene therapy CDMO/CRO offering viral vector manufacturing, biosafety testing, and integration site analysis services. Comparable to ProtaGene on cell/gene therapy analytics, with deeper manufacturing integration but narrower biotherapeutic protein characterization offerings.
  • GenScript ProBio: GenScript ProBio provides CDMO and analytical services for biologics and cell/gene therapy developers, including vector characterization and biosafety testing. Comparable to ProtaGene on gene therapy and biologics analytics with growing specialty depth, particularly in viral vector and plasmid analytics.
  • WuXi AppTec (WuXi Advanced Therapies Unit): WuXi AppTec's Advanced Therapies unit provides analytical testing and CMC services for cell and gene therapy developers, including viral vector characterization and biosafety testing. Comparable to ProtaGene on gene therapy analytics, with broader CDMO scale but less specialization in ISA and biosimilar comparability.

Broad incumbents

  • Labcorp Drug Development (formerly Covance): Labcorp Drug Development offers central lab, bioanalytical, and biologics characterization services with global lab infrastructure. Competes with ProtaGene on protein characterization and biosimilar comparability work, but with substantially broader clinical and central lab services and less ISA specialization.
  • Thermo Fisher Scientific (PPD Bioanalytical): Thermo Fisher Scientific acquired PPD and operates bioanalytical and biologics characterization labs that overlap with ProtaGene's mass spectrometry, GMP testing, and biosimilar characterization services. Has broader life sciences scale and instrument manufacturer position, but less focus on gene therapy ISA.
  • Intertek Pharmaceutical Services: Intertek Pharmaceutical Services provides analytical development, GMP testing, and biologics characterization across global labs. Comparable to ProtaGene on biologics and biosimilar testing services, though with less specialization in cell/gene therapy integration site analysis.
  • Eurofins BioPharma Product Testing: Eurofins BioPharma Product Testing is the largest global contract testing network for biopharmaceuticals, offering biologics characterization, biosimilar comparability, viral clearance, and cell/gene therapy analytics. Overlaps with ProtaGene across nearly all service lines at greater scale and broader geographic reach, though it is a portfolio rather than specialty provider.
  • Charles River Laboratories: Charles River's Biologics and Cell & Gene Therapy CDMO/CRO services include analytical method development, biosafety testing, viral clearance, and cell therapy characterization. Competes with ProtaGene on biologics characterization and cell/gene therapy analytics, with deeper CDMO integration but less specialization in ISA and biosimilar comparability.
  • SGS Health Sciences: SGS Health Sciences provides bioanalytical, biosafety, and biopharmaceutical characterization services from a global laboratory network. Overlaps with ProtaGene on biologics testing, GMP release, and biosafety testing, though at broader scale with less focus on gene therapy ISA.

Direct peers

  • BioReliance (MilliporeSigma): BioReliance, the biopharma biosafety testing arm of MilliporeSigma (Merck KGaA), offers biosafety, viral clearance, and biologics characterization services including integration site analysis. Direct competitor to ProtaGene's Cell & Gene Therapy Analytics line, particularly on ISA, viral vector testing, and GMP lot release services for biologics developers.

Market position

Strengths2 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

ProtaGene social profiles

Digital presence

ProtaGene compliance and trust

Trust signal

Compliance8 records

ProtaGene financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ProtaGene leadership team

Management profile

Number of profiles

Profiles7 records

ProtaGene funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ProtaGene M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ProtaGene

What does ProtaGene do?

ProtaGene is a contract research organization providing advanced analytical laboratory services for biopharmaceutical and cell/gene therapy developers. The company offers two integrated service lines — Biologic Drug Analytics (biotherapeutic characterization, product and process development, manufacturing and QC, biosimilar program support, clinical sample in vivo CQA mapping, and cell-based assays) and Cell & Gene Therapeutic Analytics (molecular bioanalysis, integration site analysis, vector analytics, long-read sequencing, bioinformatics, genome and gene editing analysis, gene expression analysis, and commercial patient testing) — delivered through GMP-, GLP-, GCP-, GCLP-, and CLIA-certified facilities across Germany and the United States.

Is ProtaGene a public or private company?

ProtaGene is a private company. It is classified as venture growth investor backed and is currently operating.

When was ProtaGene founded?

ProtaGene was founded in 2021. It employs 101 to 250 people.

Where is ProtaGene based?

ProtaGene is headquartered in Heilbronn, Germany, in the Europe region.

How does ProtaGene make money?

Two revenue lines are on record. Contract Research Services are the primary driver. The others are strategic Program Partnering (C-CAD).

Who are ProtaGene's main competitors?

Emerging players on record are ABL Bio, GenScript ProBio and WuXi AppTec (WuXi Advanced Therapies Unit). Broad incumbents are Labcorp Drug Development (formerly Covance), Thermo Fisher Scientific (PPD Bioanalytical), Intertek Pharmaceutical Services, Eurofins BioPharma Product Testing, Charles River Laboratories and SGS Health Sciences. BioReliance (MilliporeSigma) is listed as a direct peer.

Does ProtaGene have an API?

No public API is recorded for ProtaGene.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialProtagene Appoints Former Merck Kgaa CDMO Leader Matthias Bucerius As Chief Executive OfficerProtaGene appointed Matthias Bucerius, former Merck KGaA CDMO leader, as CEO. He will focus on predictable timelines, high data quality, and cutting-edge analytical science. The company operates four sites in Europe and North America.PR NewswireProtaGene, CGT Announces CAP & CLIA Approval for ISA TestingProtaGene has received Clinical Laboratory Improvement Amendments (CLIA) accreditation from the College of American Pathologists (CAP) for its Heidelberg site to perform Integration Site Analysis on human samples treated with lentivirus-based cell and gene therapy products. This certification authorizes testing on human specimens under U.S. federal regulations and confirms compliance with rigorous quality and regulatory standards. The accreditation strengthens ProtaGene's position as a leading provider of safety analytical assessments for biopharmaceutical partners and healthcare organizations worldwide.The Pharma LetterNew capital to advance ProtaGene's analytical leadershipGermany-headquartered contract research organization ProtaGene announced an additional investment from Ampersand Capital Partners. The article details the funding announcement but provides no further financial figures or strategic implications due to paywall restrictions. Access to the full content is restricted to registered users of The Pharma Letter.PR NewswireNew Capital Strengthens ProtaGene's Advanced Analytical Leadership in the Biologics and Cell and Gene Therapy MarketsAmpersand Capital Partners invested nearly $40 million in ProtaGene over the past year to support its biologics and cell and gene therapy analytics services. The funding enabled capacity expansions, including a new Boston headquarters and enhanced global offerings. The investment aims to meet rebounding market demand and address complex analytical challenges.AmpersandcapitalNew Capital Strengthens ProtaGene’s Advanced Analytical Leadership in the Biologics and Cell and Gene Therapy MarketsProtaGene has strengthened its analytical capabilities in the biologics and cell and gene therapy markets through new capital investments. This move aims to enhance ProtaGene's position in a growing market focused on advanced therapeutic solutions.PR NewswireProtaGene Appoints New Scientific and Commercial Leadership to Support Evolving Needs of Biologic and Cell & Gene Therapy InnovatorsProtaGene appointed Jennifer Chadwick as Chief Scientific Officer and Owen Hitchins as Chief Commercial Officer. Chadwick previously led analytical development at BioAnalytix, while Hitchins held business development roles at Covance and others. The pair will collaborate to meet evolving needs of biologic and cell and gene therapy innovators.PR NewswireProtaGene Names Pharmaceutical Industry Leader Raymond Kaiser as Chief Executive Officer to Drive Next Stages of GrowthProtaGene appointed Raymond Kaiser as CEO, effective immediately, to drive growth in its biologics and cell and gene therapy analytics. Kaiser brings over 26 years of industry experience and previously served as COO. The company will continue building capabilities after its merger with GeneWerk and partnership with Ampersand Capital.PR NewswireAnalytical Service Leaders in Biopharmaceutical and Gene Therapy Development Unify Operations and Re-brand as ProtaGeneProtagen Protein Services GmbH, BioAnalytix, Inc., and GeneWerk GmbH have completed their merger and rebranded as ProtaGene, creating a unified world-leading CRO partner for the biopharmaceutical and cell and gene therapy industries. The three legacy entities combined their protein science and gene analytics capabilities under Ampersand Capital Partners ownership, operating four sites across Europe and North America. The new integrated company positions itself to offer end-to-end analytical services from discovery through commercialization to biopharmaceutical and gene therapy developers.The Mass Spectrometry Web PortalProtaGene–Ampersand: investment, 202201 existent portfolio company after merger/acquisition of PPS GmbH + BioAnalytix + GeneWerk GmbH in 7/21ProtaGene unified operations and rebranded after merging PPS, BioAnalytix, and GeneWerk in July 2021. The combined CRO offers protein and gene analytics from discovery to commercialization, with four sites in Europe and North America. Ampersand Capital Partners owns the portfolio company.